Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide

Summary: Objective: Nutrient-stimulated gut hormone peptide YY3–36 (PYY3–36) selectively activates the neuropeptide Y2 receptor (NPY2R) and reduces energy intake in humans. We describe the discovery and pharmacology of the long-acting NPY2R agonist BI 1820237 and its potential bodyweight-lowering e...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert Augustin, Anouk Oldenburger, Tamara Baader-Pagler, Tina Zimmermann, Jens Borghardt, Jacob Hecksher-Sørensen, Angela Baljuls, Wolfgang Reindl, Bartlomiej Krawczyk, Eric Martel, Albert Brennauer, Stefan Peters, Achim Grube, Lise Biehl Rudkjaer, Peter Haebel
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Molecular Metabolism
Subjects:
PYY3–36
NPY
NPY2R
BI 1820237
Survodutide
Obesity
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877825001127
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items